About Regen Lab
Regen Lab is a company founded in 2003. It operates as a B2B. Regen Lab operates in a competitive market with competitors including Horizon Therapeutics, Histogenics, Osteal Therapeutics, Enobia Pharma and Fibrocell Science, among others.
- SectorsHealthcare
- Website regenlab.com
People of Regen Lab
4 people are tracked at Regen Lab (1 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Antoine Turzi | CEO & Founder | Leadership |
Sofia Karatsuba | HR Manager | Team |
Ahmed Tewfik Beggah | Clinical Project Manager | Team |
Ahmed Sami | Product Manager At Regenlab® Hq, United Arab Emirates, Dubai | Team |
Complete people profiles for Regen Lab
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Regen Lab
Regen Lab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Histogenics, Osteal Therapeutics, Enobia Pharma and Fibrocell Science, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. | |
| fibrocell.com | 1995 | Exton, United States | $34.66M | – | Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. | |
| zetagen.com | 2017 | Syracuse, United States | $20.35M | – | Small molecule therapeutics for bone regeneration are developed. | |
| cellphire.com | 2006 | Rockville, United States | $25.3M | 62 | Platelet-based therapeutics for hemostasis and regenerative medicine are developed. | |
| nuot.com | 2001 | Gaithersburg, United States | $69.12M | 10 | Regenerative therapies for wound care and ulcers are developed. | |
| bonetherapeutics.com | 2006 | Charleroi, Belgium | $17.87M | 20 | Cell therapy products for orthopedics and bone diseases are developed. |
Detailed competitors of Regen Lab
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regen Lab
The website of Regen Lab (regenlab.com) receives about 11K visits a month.
- Monthly visits11K
▲ 68.4% vs previous month
Websites whose visitors overlap most with Regen Lab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sernova.com | 100% | 6K | #5,531,928 | View details | |
| regenlabusa.com | 100% | 2K | – | View details | |
| lifecell.com | 81% | – | – | View details |
Latest news on Regen Lab
Complete news archive for Regen Lab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Regen Lab
10 companies that operate in the same segment as Regen Lab (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Regen Lab
Regen Lab was founded in 2003.
Regen Lab develops autologous regenerative medicines based on platelet-rich plasma (prp), focusing on providing healthcare solutions, advancing biotech innovations, regenerative medicine, and prp therapies. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
Regen Lab's top competitors include Horizon Therapeutics, ZetaGen and Angitia.